Please provide your email address to receive an email when new articles are posted on . A metallo-beta-lactam inhibitor could help fight resistance to beta-lactam antibiotics. MK-3402 was found to be ...

SAN DIEGO--(BUSINESS WIRE)--Qpex Biopharma today announced that clinical and preclinical data on its portfolio of clinical stage investigational antibiotic programs will be featured in several ...

Pfizer has just completed phase 3 trials of a new antibiotic that's active against highly resistant Gram-negative infections. It's a real superbug fighter. But what took so long? Once upon a time in a ...

Shionogi manufactures and markets cefiderocol, a beta-lactam antibiotic that utilizes a clever siderophore strategy to enter and kill multi-resistant Gram-negative pathogens. Shionogi just entered a ...

Houston, TX – New research by investigators in Ghent, Belgium shows that intravenous treatment with MK-3402, a metallo-beta-lactamase inhibitor, can be an effective strategy in fighting antimicrobial ...

New research by investigators in Ghent, Belgium shows that intravenous treatment with MK-3402, a metallo-beta-lactamase inhibitor, can be an effective strategy in fighting antimicrobial resistance.

MALVERN, Pa.--(BUSINESS WIRE)--Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with difficult-to-treat drug resistant ...

Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...

Tuojie Biotech (Shanghai) Co. Ltd. has disclosed boric acid derivatives acting as β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infections.